- Home
- LUD vs CRDL Comparison
LUD vs CRDL Comparison
Compare LUD & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUD
- CRDL
- Stock Information
- Founded
- LUD 2004
- CRDL 2017
- Country
- LUD Hong Kong
- CRDL Canada
- Employees
- LUD N/A
- CRDL N/A
- Industry
- LUD
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LUD
- CRDL Health Care
- Exchange
- LUD NYSE
- CRDL Nasdaq
- Market Cap
- LUD 96.7M
- CRDL 112.4M
- IPO Year
- LUD 2025
- CRDL N/A
- Fundamental
- Price
- LUD $5.63
- CRDL $1.44
- Analyst Decision
- LUD
- CRDL Strong Buy
- Analyst Count
- LUD 0
- CRDL 2
- Target Price
- LUD N/A
- CRDL $9.00
- AVG Volume (30 Days)
- LUD 38.7K
- CRDL 289.4K
- Earning Date
- LUD 01-01-0001
- CRDL 08-11-2025
- Dividend Yield
- LUD N/A
- CRDL N/A
- EPS Growth
- LUD N/A
- CRDL N/A
- EPS
- LUD N/A
- CRDL N/A
- Revenue
- LUD $44,863,430.00
- CRDL N/A
- Revenue This Year
- LUD N/A
- CRDL N/A
- Revenue Next Year
- LUD N/A
- CRDL N/A
- P/E Ratio
- LUD N/A
- CRDL N/A
- Revenue Growth
- LUD N/A
- CRDL N/A
- 52 Week Low
- LUD $3.40
- CRDL $0.77
- 52 Week High
- LUD $9.52
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- LUD N/A
- CRDL 56.90
- Support Level
- LUD N/A
- CRDL $1.14
- Resistance Level
- LUD N/A
- CRDL $1.42
- Average True Range (ATR)
- LUD 0.00
- CRDL 0.10
- MACD
- LUD 0.00
- CRDL 0.01
- Stochastic Oscillator
- LUD 0.00
- CRDL 83.33
About LUD LUDA TECHNOLOGY GROUP LIMITED
Luda Technology Group Ltd is a company that is principally engaged in the manufacture and sale of stainless steel and carbon steel flanges and fittings products and trading of steel pipes, valves, and other steel tubing products.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.